Literature DB >> 2298153

Effects of prostaglandin F2 alpha on bone formation and resorption in cultured neonatal mouse calvariae: role of prostaglandin E2 production.

L G Raisz1, C B Alander, P M Fall, H A Simmons.   

Abstract

Although most studies show that prostaglandin E2 (PGE2) is the most potent and effective of the prostanoids in bone, recent data in cell culture suggest that PGF2 alpha may have unique effects, particularly on cell replication. The present study was undertaken to compare the effects of PGF2 alpha and PGE2 in cultured neonatal mouse parietal bones by simultaneous measurement of bone resorption as release of previously incorporated 45Ca, bone formation as incorporation of [3H]proline into collagenase-digestible (CDP) and noncollagen protein, and DNA synthesis as incorporation of [3H]thymidine. PGF2 alpha was less effective than PGE2 as a stimulator of bone resorption, and its effects were partially inhibited by indomethacin and markedly inhibited by glucocorticoids. In contrast, the resorptive response to PGE2 was unaffected by indomethacin and only partially inhibited by cortisol. PGF2 alpha had little effect on bone formation, in contrast to the biphasic effect of PGE2, which inhibited labeling of CDP in the absence of cortisol and stimulated CDP labeling in the presence of cortisol. PGF2 alpha increased thymidine incorporation into DNA, but the effect was smaller than that of PGE2 and was inhibited by indomethacin. These observations suggested that PGF2 alpha might act in part by stimulating PGE2 production. By RIA, PGE2 concentrations were increased in the medium of bones treated with PGF2 alpha, and this increase was blocked by indomethacin. By HPLC, bones prelabeled with [3H]arachidonic acid showed an increase in labeled PGE2 release, and RIA showed an increase in PGE2 after PGF2 alpha treatment. These results indicate that PGF2 alpha is a relatively weak agonist in bone compared to PGE2 and that some of the effects of PGF2 alpha on bone resorption, formation, and cell replication may be mediated by an increase in endogenous PGE2 production.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2298153     DOI: 10.1210/endo-126-2-1076

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

1.  Alteration of femoral bone morphology and density in COX-2-/- mice.

Authors:  Galen Robertson; Chao Xie; Di Chen; Hani Awad; Edward M Schwarz; Regis J O'Keefe; Robert E Guldberg; Xinping Zhang
Journal:  Bone       Date:  2006-05-30       Impact factor: 4.398

2.  Regulation of Nur77 gene expression by prostanoids in cementoblastic cells.

Authors:  Sanda M Moldovan; Jeanne M Nervina; Sotirios Tetradis; Paulo M Camargo
Journal:  Arch Oral Biol       Date:  2009-02-23       Impact factor: 2.633

Review 3.  Prostaglandins: mechanisms of action and regulation of production in bone.

Authors:  L G Raisz; C C Pilbeam; P M Fall
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

4.  Prostaglandin expression profile in hypoxic osteoblastic cells.

Authors:  Christina M Lee; Damian C Genetos; Alice Wong; Clare E Yellowley
Journal:  J Bone Miner Metab       Date:  2009-05-28       Impact factor: 2.626

5.  Prostaglandin F2 alpha-stimulated phospholipase D activation in osteoblast-like MC3T3-E1 cells: involvement in sustained 1,2-diacylglycerol production.

Authors:  T Sugiyama; T Sakai; Y Nozawa; N Oka
Journal:  Biochem J       Date:  1994-03-01       Impact factor: 3.857

6.  HSP90 inhibitors potentiate PGF2α-induced IL-6 synthesis via p38 MAP kinase in osteoblasts.

Authors:  Kazuhiko Fujita; Haruhiko Tokuda; Gen Kuroyanagi; Naohiro Yamamoto; Shingo Kainuma; Tetsu Kawabata; Go Sakai; Rie Matsushima-Nishiwaki; Osamu Kozawa; Takanobu Otsuka
Journal:  PLoS One       Date:  2017-05-19       Impact factor: 3.240

7.  Disproportionate Effect of Sub-Micron Topography on Osteoconductive Capability of Titanium.

Authors:  Juri Saruta; Nobuaki Sato; Manabu Ishijima; Takahisa Okubo; Makoto Hirota; Takahiro Ogawa
Journal:  Int J Mol Sci       Date:  2019-08-18       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.